WO2013006792A1 - Composés antiviraux - Google Patents
Composés antiviraux Download PDFInfo
- Publication number
- WO2013006792A1 WO2013006792A1 PCT/US2012/045761 US2012045761W WO2013006792A1 WO 2013006792 A1 WO2013006792 A1 WO 2013006792A1 US 2012045761 W US2012045761 W US 2012045761W WO 2013006792 A1 WO2013006792 A1 WO 2013006792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- independently
- phenyl
- Prior art date
Links
- 0 C*(C([C@](Cc1ccccc1)*(C)(C)C(CC(F)(F)F)=O)=O)c(cc1)cc2c1OCO2 Chemical compound C*(C([C@](Cc1ccccc1)*(C)(C)C(CC(F)(F)F)=O)=O)c(cc1)cc2c1OCO2 0.000 description 4
- JDYSMMLVEKFSIF-UHFFFAOYSA-N C=Cc1cc(CC(C(F)(F)F)=O)ccc1 Chemical compound C=Cc1cc(CC(C(F)(F)F)=O)ccc1 JDYSMMLVEKFSIF-UHFFFAOYSA-N 0.000 description 1
- KUCOGTMSXXOPMA-DEOSSOPVSA-N CC(C)(C(N[C@@H](Cc1ccccc1)C(N(C)c1ccc2OCOc2c1)=O)=O)[n]1nc(C2CC2)c(CCO)c1C Chemical compound CC(C)(C(N[C@@H](Cc1ccccc1)C(N(C)c1ccc2OCOc2c1)=O)=O)[n]1nc(C2CC2)c(CCO)c1C KUCOGTMSXXOPMA-DEOSSOPVSA-N 0.000 description 1
- AISVZOAYJVIHHK-FQEVSTJZSA-N Cc1c(CCO)c(C(F)(F)F)n[n]1CC(N[C@@H](Cc1ccccc1)C(N(C)c1ccc2OCOc2c1)=O)=O Chemical compound Cc1c(CCO)c(C(F)(F)F)n[n]1CC(N[C@@H](Cc1ccccc1)C(N(C)c1ccc2OCOc2c1)=O)=O AISVZOAYJVIHHK-FQEVSTJZSA-N 0.000 description 1
- UTAQSCXPUIZDRN-LPECGTQYSA-M Cc1c(CCO)c(C2CC2)n[n]1CC(N[C@@H](Cc1ccccc1)C(N(C)[AlH2])=O)=O Chemical compound Cc1c(CCO)c(C2CC2)n[n]1CC(N[C@@H](Cc1ccccc1)C(N(C)[AlH2])=O)=O UTAQSCXPUIZDRN-LPECGTQYSA-M 0.000 description 1
- UGAFCCZPMICRJT-UHFFFAOYSA-N Cc1c(CO)nc(C2CC2)[nH]1 Chemical compound Cc1c(CO)nc(C2CC2)[nH]1 UGAFCCZPMICRJT-UHFFFAOYSA-N 0.000 description 1
- ADPRIAVYIGHFSO-UHFFFAOYSA-N Fc1nccc(I)c1 Chemical compound Fc1nccc(I)c1 ADPRIAVYIGHFSO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention relates to novel compounds as anti-viral agents, which can be useful in the treatment of viral infections such as HIV, HBV and HCV; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
- HIV is released from the infected cells as an immature, non-infectious particle containing a spherical protein shell of approximately 5,000 Gag molecules underneath the viral membrane.
- MA matrix
- CA capsid
- NC nucleocapsid
- the last but critical proteolytic cleavage step of CA-SPl generates a mature p24 CA protein, which is capable of forming the higher-order complexes that comprise the mature viral core. In the absence of this maturation, viral particles remain to be non-infectious.
- the resent invention provides a compound of formula I,
- W is 5 to 7-membered monocyclic carbocycle or heterocycle; each of Ri and R 2 is independently H, (Ci-C4)alkyl, (C 3 -C 5 )cycloalkyl, hydroxyl, fluoro, or NR b R c , or Ri and R 2 together form (C 3 -C 5 )cycloalkyl; R 3 is phenyl, or heteroaryl;
- R4 is H, (Ci-C 4 )alkyl, or (C 3 -C 7 )cycloalkyl;
- R 5 is (CRgR q-cycloalkyl, (CRgRc>)q-aryl, or (CRgR 9 ) q -heterocycle; each of Rg and R 9 is independently H, (Ci-C 4 )alkyl, hydroxyl, fluoro, or NRbRc, or R 8 and R 9 together form (C 3 -C5)cycloalkyl; each of Rb and R c is independently hydrogen or alkyl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle; each q is independently 0, 1, 2, 3, or 4; and n is 1 or 2.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound as described herein and a pharmaceutically-acceptable carrier.
- the present invention provides a method for treating or preventing a viral infection in a mammalian species in need thereof, the method comprising administering to the mammalian species a therapeutically effective amount of at least one compound as described herein.
- the present invention provides a method for treating or preventing HIV infection in a mammalian species in need thereof, the method comprising administering to the mammalian species a therapeutically effective amount of at least one compound as described herein.
- alkyl and “alk” refer to a straight or branched chain alkane
- hydrocarbon radical containing from 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms.
- alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
- (Ci-C4)alkyl refers to a straight or branched chain alkane (hydrocarbon) radical containing from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, and isobutyl.
- alkyl and alk may include substituted alkyl.
- Substituted alkyl refers to an alkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include but are not limited to one or more of the following groups: hydrogen, halogen (e.g.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , R c and R d is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R s is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.
- groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.
- alkenyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon-carbon double bond.
- C 2 -C 6 alkenyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 6 carbon atoms and at least one carbon-carbon double bond, such as ethylenyl, propenyl, 2-propenyl, (E)-but-2-enyl, (Z)-but- 2-enyl, 2-methy(E)-but-2-enyl, 2-methy(Z)-but-2-enyl, 2,3-dimethy-but-2-enyl, (Z)-pent-2- enyl, (E)-pent-l-enyl, (Z)-hex-l-enyl, (E)-pent-2-enyl, (Z)-hex-2-enyl, (E)-hex-2-enyl, (Z)- hex-l-enyl, (E)-hex-l-enyl, (E)-hex-l-enyl, (E)-hex
- alkenyl may include substituted alkenyl.
- substituted alkenyl refers to an alkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- substituents include but are not limited to one or more of the following groups: hydrogen, halogen (e.g.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , Rc and Rj is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and Rc together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.
- the exemplary substitutents can themselves be optionally substituted.
- alkynyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond.
- Exemplary such groups include ethynyl.
- C 2 -C 6 alkynyl refers to a straight or branched chain hydrocarbon radical containing from 2 to 6 carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, prop-l-ynyl, prop-2-ynyl, but-l-ynyl, but-2-ynyl, pent-l-ynyl, pent-2-ynyl, hex-l-ynyl, hex-2-ynyl, hex-3-ynyl.
- alkynyl may include substituted alkynyl.
- Substituted alkynyl refers to an alkynyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- cycloalkyl refers to a fully saturated cyclic hydrocarbon group containing from 1 to 4 rings and 3 to 8 carbons per ring.
- C3-C7 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
- cycloalkyl may include substituted cycloalkyl.
- Substituted cycloalkyl refers to a cycloalkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , Rc and Rj is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and Rc together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.
- exemplary substitutents can themselves be optionally substituted.
- exemplary substituents also include spiro-attached or fused cylic substituents, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substitutents can themselves be optionally substituted.
- cycloalkenyl refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 8 carbons per ring. Exemplary such groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, etc.
- cycloalkenyl may include substituted cycloalkenyl.
- substituted cycloalkenyl refers to a cycloalkenyl group substituted with one more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , Rc and Rj is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and Rc together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.
- exemplary substitutents can themselves be optionally substituted.
- exemplary substituents also include spiro-attached or fused cylic substituents, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- aryl refers to cyclic, aromatic hydrocarbon groups that have 1 to 5 aromatic rings, especially monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two or more aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl, phenanthrenyl and the like).
- aryl may include substituted aryl.
- substituted aryl refers to an aryl group substituted by one or more substituents, preferably 1 to 3 substituents, at any available point of attachment.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , Rc and Rj is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.
- exemplary substitutents can themselves be optionally substituted.
- exemplary substituents also include fused cylic groups, especially fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- carrier refers to a fully saturated or partially saturated cyclic hydrocarbon group containing from 1 to 4 rings and 3 to 8 carbons per ring, or cyclic, aromatic hydrocarbon groups that have 1 to 5 aromatic rings, especially monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl.
- carrier encompasses cycloalkyl, cycloalkenyl, cycloalkynyl and aryl as defined hereinabove.
- Carbocycle may include substituted carbocycle.
- substituted carbocycle refers to carbocycle or carbocyclic groups substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- substituents include, but are not limited to, those described above for substituted cycloalkyl, substituted cycloalkenyl, substituted cycloalkynyl and substituted aryl.
- substituents also include spiro- attached or fused cyclic substituents at any available point or points of attachment, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- heterocycle and “heterocyclic” refer to fully saturated, or partially or fully unsaturated, including aromatic (i.e., “heteroaryl”) cyclic groups (for example, 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 8 to 16 membered tricyclic ring systems) which have at least one heteroatom in at least one carbon atom-containing ring.
- aromatic i.e., "heteroaryl”
- cyclic groups for example, 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 8 to 16 membered tricyclic ring systems
- Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3, or 4
- heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
- heteroarylium refers to a heteroaryl group bearing a quaternary nitrogen atom and thus a positive charge.
- the heterocyclic group may be attached to the remainder of the molecule at any heteroatom or carbon atom of the ring or ring system.
- Exemplary monocyclic heterocyclic groups include azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl,
- hexahydrodiazepinyl 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-l,l-dioxothienyl, and the like.
- bicyclic heterocyclic groups include indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, benzo[d][l,3]dioxolyl, 2,3- dihydrobenzo[b][l,4]dioxinyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl,
- Exemplary tricyclic heterocyclic groups include carbazolyl, benzindolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- heterocycle may include substituted heterocycle.
- Substituted heterocycle and “substituted heterocyclic” (such as “substituted heteroaryl”) refer to heterocycle or heterocyclic groups substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment.
- substituents include but are not limited to one or more of the following groups: hydrogen, halogen (e.g.
- each occurrence of R a is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; each occurrence of R b , R c and R d is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and each occurrence of R» is independently alkyl, cycloalkyl, alkenyl, cycloal
- exemplary substitutents can themselves be optionally substituted.
- exemplary substituents also include spiro-attached or fused cyclic substituents at any available point or points of attachment, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- alkylamino refers to a group having the structure -NHR', wherein R' is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cyclolakyl, as defined herein.
- alkylamino groups include, but are not limited to, methylamino, ethylamino, n- propylamino, iso-propylamino, cyclopropylamino, n-butylamino, tert-butylamino, neopentylamino, n-pentylamino, hexylamino, cyclohexylamino, and the like.
- dialkylamino refers to a group having the structure -NRR', wherein R and R' are each independently alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cyclolalkenyl, aryl or substituted aryl, heterocylyl or susbstituted heterocyclyl, as defined herein. R and R' may be the same or different in an dialkyamino moiety.
- dialkylamino groups include, but are not limited to, dimethylamino, methyl ethylamino, diethylamino, methylpropylamino, di(n-propyl)amino, di(iso- propyl)amino, di(cyclopropyl)amino, di(n-butyl)amino, di(tert-butyl)amino,
- R and R' are linked to form a cyclic structure.
- the resulting cyclic structure may be aromatic or non-aromatic.
- Examples of cyclic diaminoalkyl groups include, but are not limited to, aziridinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, imidazolyl, 1,3,4-trianolyl, and tetrazolyl.
- halogen or halo refer to chlorine, bromine, fluorine or iodine.
- any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
- the compounds of the present invention may form salts which are also within the scope of this invention.
- Reference to a compound of the present invention is understood to include reference to salts thereof, unless otherwise indicated.
- the term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases.
- zwitterions inner salts
- inner salts may be formed and are included within the term “salt(s)" as used herein.
- Salts of the compounds of the present invention may be formed, for example, by reacting a compound I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- the compounds of the present invention which contain a basic moiety may form salts with a variety of organic and inorganic acids.
- Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides,
- methanesulfonates methanesulfonates, naphthalenesulfonates (e.g., 2-naphthalenesulfonates), nicotinates, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g., 3-phenylpropionates), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates, tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.
- naphthalenesulfonates e.g., 2-naphthalenesulfonates
- nicotinates e.g., nitrates, oxalates
- pectinates persulfates
- the compounds of the present invention which contain an acidic moiety may form salts with a variety of organic and inorganic bases.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl) ethylenediamine), N-methyl-D- glucamines, N-methyl-D-glycamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
- prodrugs and solvates of the compounds of the invention are also contemplated herein.
- the term "prodrug" as employed herein denotes a compound that, upon
- Solvates of the compounds of the present invention include, for example, hydrates.
- All stereoisomers of the present compounds are contemplated within the scope of this invention.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers (e.g., as a pure or substantially pure optical isomer having a specified activity), or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention may have the S or R configuration as defined by the International Union of Pure and Applied Chemistry (IUPAC) 1974
- racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography.
- the individual optical isomers can be obtained from the racemates by any suitable method, including without limitation, conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
- Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 90%, for example, equal to greater than 95%, equal to or greater than 99% of the compounds ("substantially pure” compounds), which is then used or formulated as described herein. Such “substantially pure” compounds of the present invention are also contemplated herein as part of the present invention.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90: 10, 95:5, 96:4, 97:3, 98:2, 99: 1, or 100:0 isomer ratios are all contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- the present invention also includes isotopically labeled compounds, which are identical to the compounds disclosed herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, U C, 14 C, 15 N, 18 0, 17 0, 31 P,
- isotopically labeled compounds can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl,
- diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
- the compounds, as described herein, may be substituted with any number of substituents or functional moieties.
- substituted refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
- substituents may be either the same or different at every position.
- substituted is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
- heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.
- this invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
- Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment, for example, of infectious diseases or proliferative disorders.
- stable as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
- the present invention provides a compound of the formula (I):
- W is 5 to 7-membered monocyclic carbocycle or heterocycle; each of Ri and R 2 is independently H, (Ci-C 4 )alkyl, (C 3 -C 5 )cycloalkyl, hydroxyl, fluoro, or NR b R c , or Ri and R 2 together form (C 3 -C 5 )cycloalkyl;
- R 3 is phenyl, or heteroaryl
- R4 is H, (Ci-C 4 )alkyl, or (C 3 -C 7 )cycloalkyl;
- R 5 is (CRgR 9 ) q -cycloalkyl, (CRgR 9 ) q -aryl, or (CR 8 Rc)) q -heterocycle; each of Rg and R9 is independently H, (Ci-C 4 )alkyl, hydroxyl, fluoro, or NR b R c , or Rg and R9 together form (C 3 -C5)cycloalkyl; each of R b and R c is independently hydrogen or alkyl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; each q is independently 0, 1, 2, 3, or 4; and n is 1 or 2.
- W is 5-membered heteroaryl, 6-membered heteroaryl, or phenyl, in which said heteroaryl and phenyl are each independently substituted with (R 6 ) m ; each of Ri and R 2 is independently H or (Ci-C 4 )alkyl; R 3 is phenyl, or heteroaryl;
- R4 is H, (Ci-C 4 )alkyl, or (C 3 -C 7 )cycloalkyl;
- the compound of Formula (I) has the structure of
- W is 5-membered heteroaryl, in which said heteroaryl is substituted with (Re) m - In certain other embodiments, wherein W is 6- membered heteroaryl, in which said heteroaryl is substituted with ( ⁇ m - In yet other embodiments, W is phenyl, in which said phenyl is independently substituted with (R ⁇ ),
- the compound of Formula (I) has the structure of Formula (III): wherein denotes ; each of Zl, Z2, Z3, Z4 and Z5 is independently carbon or nitrogen, provided that at least one of Z ls Z 2 , Z 3 , Z 4 and Z 5 is nitrogen; and Ri, R 2 , R 3 , R4, R 5 , and R 6 are as defined in claim 2, and m is 0, 1 , 2, or 3.
- the compound of Formula (I) has the structure of Formula (IV):
- each of Z 2 , Z 3 , Z 4 and Z 5 is independently carbon or nitrogen; Yi is oxygen or sulfur; and Ri, R 2 , R 3 , R4, R5, and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (IVa):
- R ls R 2 , R 3 , R4, R 5 , and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (IVb):
- R ls R 2 , R3, R4, R5, and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (IVc):
- R ls R 2 , R3, R4, R5, and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (IVd):
- R ls R 2 , R3, R4, R 5 , and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (V):
- R ls R 2 , R3, R4, R5, and R 6 are as defined in claim 2, and m is 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (VI):
- R ls R 2 , R3, R4, R 5 , and R 6 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (VII):
- each of Xi, X 2 , X 3 , X 4 , X5 and X 6 is independently carbon or nitrogen, provided that at least one of Xi, X 2 , X 3 , X 4 , X5 and X 6 is nitrogen; and Ri, R 2 , R3, R 4 , R5, and 5 are as defined in claim 2, and m is 0, 1, 2, or 3.
- the compound of Formula (I) has the structure of Formula (Vila):
- each of X 4 , X5 and X 6 is independently carbon or nitrogen, provided that only one of X 4 , X5 and X 6 is nitrogen, and the remaining of X 4 , X5 and X 6 is carbon; and Ri, R 2 , R3, R4, R5, and R6 are as defined in claim 2, and m is 0, 1 , or 2.
- the compound of Formula (I) has the structure of Formula (VIII):
- R l s R 2 , R3, R4, R5, and R 6 are as defined in claim 2, and m is 0, 1 , 2, or 3.
- each of Ri and R 2 is independently H.
- R 3 is phenyl.
- R 3 is phenyl substituted with one to three substituents selected from H, (Ci-C 4 )alkyl, 0-(Ci-C 4 )alkyl, halogen, nitro, CN, CF 3 , and OCF 3 .
- R3 is unsubstituted phenyl.
- R3 is heteroaryl substituted with one to three substituents selected from H, (Ci-C 4 )alkyl, 0-(Ci- C 4 )alkyl, halogen, nitro, CN, CF 3 , and OCF 3 . In yet other embodiments, R 3 is unsubstituted heteroaryl.
- R4 is H. In certain other embodiments, R 4 is (Ci- C 4 )alkyl. In yet other embodiments, R 4 is methyl.
- R 5 is (CH 2 ) q -cycloalkyl, (CH 2 ) q -aryl, or (CH 2 ) q - heteroaryl, in which q is 0 or 1.
- R 5 is aryl, or heteroaryl.
- R 5 is phenyl.
- R 5 is pyridyl.
- R 5 is aryl (e.g., phenyl) or heteroaryl (e.g., pyridyl,
- each of R 8 and R 9 is independently H or (Ci-C 4 )alkyl
- each occurrence of R a , R b , and R c is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycle, or aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and
- each q is independently 0, 1, 2, 3, or 4.
- R 5 is phenyl or heteroaryl substituted with one to four substituents selected from hydrogen, halogen, cyano, nitro, CF 3 , OCF 3 , (Ci-C 4 )alkyl, (C 3 - Cy)cycloalkyl, 3-10 membered monocyclic or bicyclic heterocycle containing at least one heteroatom selected from N, O and S, phenyl, naphthyl, (CH 2 ) q -OH, (CH 2 ) q -0-(Ci-C 4 )alkyl, (CH 2 ) q -NR b R c , (CH 2 ) q -(C 3 -C 7 )cycloalkyl, , (CH 2 ) q -phenyl, and (CH 2 ) q -heteroaryl;
- each occurrence of R b , and R c is independently hydrogen, (Ci-C 4 )alkyl, (C 3 -C 7 )cycloalkyl, 3- 10 membered monocyclic or bicyclic heterocycle containing at least one heteroatom selected from N, O and S, or aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and
- each q is independently 0, 1, 2, 3, or 4.
- each of R 8 and R 9 is independently H or (Ci-C 4 )alkyl
- each occurrence of R a , R b , and R c is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycle, or aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and each q is independently 0, 1, 2, 3, or 4.
- each occurrence of R b , and R c is independently hydrogen, (Ci-C 4 )alkyl, (C 3 -C 7 )cycloalkyl, 3- 10 membered monocyclic or bicyclic heterocycle containing at least one heteroatom selected from N, O and S, or aryl, or said R b and R c together with the N to which they are bonded optionally form a heterocycle; and each q is independently 0, 1, 2, 3, or 4.
- each occurrence of R b , and R c is independently hydrogen or (Ci-C 4 )alkyl, or said R b and R c together with the N to which they are bonded optionally form a 3-8 membered heterocycle.
- the present invention provides a compound selected from Examples 1 through 52 as described herein.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound described herein and a pharmaceutically-acceptable carrier or diluent.
- the present invention provides a method for treating or preventing a viral infection in a mammalian species in need thereof, the method comprising administering to the mammalian species a therapeutically effective amount of at least one compound described herein.
- the viral infection is HIV infection.
- the viral infection is HBV infection.
- the viral infection is HCV infection.
- the viral infection is influenza A virus infection, severe acute respiratory syndrome coronavirus infection or vaccinia virus infection.
- the present invention provides a method for treating or preventing HIV infection in a mammalian species in need thereof, the method comprising administering to the mammalian species a therapeutically effective amount of at least one compound described herein.
- the compounds of the present invention may be synthesized using conventional techniques known in the art. Advantageously, these compounds are conveniently synthesized from readily available starting materials. Following are general synthetic schemes for manufacturing compounds of the present invention. These schemes are illustrative and are not meant to limit the possible techniques one skilled in the art may use to manufacture compounds disclosed herein. Different methods will be evident to those skilled in the art. Additionally, the various steps in the synthesis may be performed in an alternate sequence or order to give the desired compound(s). All documents cited herein are incorporated herein by reference in their entirety.
- Step 1 Reaction of ketone I with a base, such as sodium hydride, potassium tert-butoxide or sodium tert-butoxide, followed by treatment with the ester R 2 COOR', affords the carbonyl ketone intermediate II.
- a base such as sodium hydride, potassium tert-butoxide or sodium tert-butoxide
- intermediate XII Treatment of intermediate XII with a base, such as n-BuLi, LDA, LiHMDS, in the solvent such as DME, dioxane, THF and so on, and then diethyl carbonate was added when Y is methyl, or MeCN was added when Y is halogen followed by treatment with TMSC1 and ethanol, affords the intermediate XXII.
- a base such as n-BuLi, LDA, LiHMDS
- bromoethane and so on in the presence of a base, such as sodium hydride, potassium carbonate, followed by addition of another base, such as lithium hydroxide, or sodium hydroxide, or potassium hydroxide, affords the intermediate XXIX.
- a base such as sodium hydride, potassium carbonate
- another base such as lithium hydroxide, or sodium hydroxide, or potassium hydroxide
- Step 3 Treatment of intermediate XXIX with a chlorination reagent, such as thionyl chloride, affords chloromethylpyrazole intermediate XXX.
- a chlorination reagent such as thionyl chloride
- intermediate XXX Treatment of intermediate XXX with a cyanidation reagent, such as NaCN, KCN, TMSCN, in the presence of a base, such as sodium carbonate, potassium carbonate, affords the intermediateXXXI.
- a cyanidation reagent such as NaCN, KCN, TMSCN
- a base such as sodium carbonate, potassium carbonate
- Step 2 Reaction of the amine XXXV and N-Boc-Phenylalanine in the presence of a condensating agent, such as HOBT/EDCI, HATU, HBTU, PyBOP, BOPC1, or a BOP reagent, and a base such as TEA, DIPEA or DMAP, in the solvent such as DCM, DMF, THF and so on, affords the amide compounds XXXVI.
- a condensating agent such as HOBT/EDCI, HATU, HBTU, PyBOP, BOPC1, or a BOP reagent
- a base such as TEA, DIPEA or DMAP
- This invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one of the compounds as described herein or a pharmaceutically-acceptable salt or solvate thereof, and a pharmaceutically-acceptable carrier.
- pharmaceutically-acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
- a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as butylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ring
- certain embodiments of the present pharmaceutical agents may be provided in the form of pharmaceutically-acceptable salts.
- pharmaceutically-acceptable salt refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- lactate lactate
- phosphate tosylate
- citrate maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- the pharmaceutically acceptable salts of the subject compounds include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from nontoxic organic or inorganic acids.
- such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, butionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
- the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases.
- pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine.
- a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine.
- Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine,
- wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polybutylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
- the amount of active ingredient, which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
- this amount will range from about 1% to about 99% of active ingredient, preferably from about 5% to about 70%, most preferably from about 10% to about 30%.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouthwashes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol;
- pharmaceutically-acceptable carriers such as sodium citrate or dicalcium phosphate
- fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid
- binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia
- humectants such as glycerol
- disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium carbonate, and sodium starch glycolate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and polyethylene oxide-polybutylene oxide copolymer; absorbents, such as kaolin and bentonite clay;
- compositions such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents.
- the pharmaceutical compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxybutylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxybutylmethyl cellulose in varying butortions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isobutyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, butylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- cyclodextrins e.g., hydroxybutyl-beta-
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active pharmaceutical agents of the invention.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active pharmaceutical agents of the invention.
- administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier and with any preservatives or buffers which may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary butellants, such as chlorofluorohydrocarbons and volatile unsubstituted
- hydrocarbons such as butane and butene.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving, or dispersing the pharmaceutical agents in the buter medium.
- Absorption enhancers can also be used to increase the flux of the pharmaceutical agents of the invention across the skin. The rate of such flux can be controlled, by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral
- administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- One strategy for depot injections includes the use of polyethylene oxide-polybutylene oxide copolymers wherein the vehicle is fluid at room temperature and solidifies at body temperature.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue.
- biodegradable polymers such as polylactide-polyglycolide.
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue.
- compositions containing, for example, 0.1% to 99.5% (more preferably, 0.5%> to 90%>) of active ingredient in combination with a pharmaceutically acceptable carrier.
- the compounds and pharmaceutical compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
- the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, the compound of the present invention may be administered concurrently with another anti-HCV agent), or they may achieve different effects (e.g., control of any adverse effects).
- the compounds of the invention may be administered intravenously,
- the compounds may be used to treat arthritic conditions in mammals (i.e., humans, livestock, and domestic animals), birds, lizards, and any other organism, which can tolerate the compounds.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of
- Example 30 1H NMR (400 MHz, CDC1 3 ) ⁇ 7.28 - 7.28 (m, 1H), 7.26 - 7.20 (m, 3H), 6.95
- MT2rep assay MT2 cells are pelleted by centrifugation and re-suspended with appropriate volume of RPMI 1640 (10%> FBS) to give a cell density about 1.34x l0 5 /ml.
- HIV-l(NL4-3) stock is added to the above MT2 cells to give a MOI about 0.01 TCID50 per cell.
- 90 ⁇ of MT2 cells/HIV-1 mixture is added to 384-well antiviral assay plates containing compounds and 45 ⁇ , of MT2 cells (1.34> ⁇ 10 5 /ml, without virus addition) is added to 384-well cytotoxicity assay plates containing compounds.
- the assay plates are incubated in a 5% C0 2 incubator at 37°C for 3 days. Three days post MT2 infection, ⁇ per well of supernatant from 384-well antiviral assay plates is transferred to a new 384-well plate and 40 ⁇ .
- JC53BL cells 0.4xl0 6 cells/ml
- ⁇ -Gal activity is measured as following.
- the compound cytotoxicity is measured three days post MT2 seeding by Celltiter Glo kit with conditions recommended by Promega except that 10 ⁇ ⁇ per well of reagent is added.
- IC50 and CC50 is calculated with GraphPadPrism5.00 (four-parameter logistic equation).
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, dans laquelle les symboles sont tels que définis dans la description ; une composition pharmaceutique en comportant, un procédé pour le traitement ou la prévention d'une infection virale telle que le VIH au moyen de ladite composition.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110190069.1 | 2011-07-07 | ||
CN201110190069.1A CN102863512B (zh) | 2011-07-07 | 2011-07-07 | 抗病毒化合物 |
US201161507309P | 2011-07-13 | 2011-07-13 | |
US61/507,309 | 2011-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013006792A1 true WO2013006792A1 (fr) | 2013-01-10 |
Family
ID=47437468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/045761 WO2013006792A1 (fr) | 2011-07-07 | 2012-07-06 | Composés antiviraux |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102863512B (fr) |
WO (1) | WO2013006792A1 (fr) |
Cited By (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110296A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Composés thérapeutiques pour le traitement d'infections virales |
WO2014110298A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Hétéroaryles à 5 chaînons et leur utilisation comme agents antiviraux |
WO2014110297A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Dérivés de (hétéro)arylacétamide servant d'agents antirétroviraux |
WO2014134566A2 (fr) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Composés thérapeutiques |
WO2015006733A1 (fr) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih |
WO2015006731A1 (fr) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih |
WO2016036759A1 (fr) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Méthodes de traitement ou de prévention du vih chez des patients au moyen d'une combinaison de ténofovir alafénamide et de dolutégravir |
WO2016105564A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Dérivés de quinazoline utilisés pour traiter le vih |
WO2016106237A1 (fr) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique |
WO2016105532A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Composés de pyrimidine fusionnés pour le traitement du vih |
WO2016105534A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Composés isoindoline pour le traitement du vih |
WO2016141092A1 (fr) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll |
WO2016161382A1 (fr) | 2015-04-02 | 2016-10-06 | Gilead Sciences, Inc. | Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique |
WO2017035230A1 (fr) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Modulateurs deutérés du récepteur toll |
WO2017059120A1 (fr) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Composés et combinaisons pour le traitement du vih |
WO2017106346A2 (fr) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Anticorps neutralisants le virus de l'immunodéficience humaine |
WO2018035359A1 (fr) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih |
WO2018042332A1 (fr) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons, utilisations et traitements correspondants |
WO2018042331A1 (fr) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons, utilisations et traitements correspondants |
WO2018045144A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Composés modulateurs du recepteur de type toll |
WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
WO2018051250A1 (fr) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc |
WO2018064080A1 (fr) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Dérivés d'acide benzothiazol-6-yl-acétique et leur utilisation pour le traitement d'une infection par le vih |
WO2018081292A1 (fr) | 2016-10-27 | 2018-05-03 | Gilead Sciences, Inc. | Formes cristallines de base libre de darunavir, hydrate, solvates et sels de celui-ci |
EP3321270A1 (fr) | 2014-06-20 | 2018-05-16 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2,5-méthanopyrido [1', 2' : 4.5] pyrazino[2,1-b] oxazepin-8-olate |
WO2018127800A1 (fr) | 2017-01-03 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2018127801A1 (fr) | 2017-01-03 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2018144390A1 (fr) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Formes cristallines de ténofovir alafénamide |
WO2018145021A1 (fr) | 2017-02-06 | 2018-08-09 | Gilead Sciences, Inc. | Analogues d'atazanavir (atv) pour traiter des infections par le vih |
WO2018203235A1 (fr) | 2017-05-02 | 2018-11-08 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2018237148A1 (fr) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Anticorps multispécifiques ciblant gp120 et cd3 du vih |
WO2019027920A1 (fr) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | Formes cristallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement d'infections virales |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2019035973A1 (fr) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc | Formes de sel choline d'un inhibiteur de la capside du vih |
WO2019035904A1 (fr) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc. | Formes solides d'un inhibiteur de capside de vih |
WO2019040102A1 (fr) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
WO2019057946A1 (fr) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d |
WO2019075291A1 (fr) | 2017-10-13 | 2019-04-18 | Gilead Sciences, Inc. | Dérivés de 1-benzyl-2-imino-4-phényl-5-oxoimidazolidine utilisés en tant qu'inhibiteurs de la protéase du vih |
WO2019084020A1 (fr) | 2017-10-24 | 2019-05-02 | Gilead Sciences, Inc. | Méthodes de traitement de patients co-infectés par un virus et la tuberculose |
CN109824756A (zh) * | 2019-03-19 | 2019-05-31 | 山东大学 | 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用 |
WO2019144015A1 (fr) | 2018-01-19 | 2019-07-25 | Gilead Sciences, Inc. | Métabolites du bictégravir |
US10370358B2 (en) | 2011-07-06 | 2019-08-06 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
WO2019161017A1 (fr) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih |
WO2019193542A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 2'3'-cycliques |
WO2019193533A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 2'2'-cycliques |
WO2019193543A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3'-cycliques |
WO2019198024A1 (fr) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
EP3564244A1 (fr) | 2014-06-20 | 2019-11-06 | Gilead Sciences, Inc. | Formes cristallines du (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazépine-10-carboxamide |
WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
WO2019244066A2 (fr) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020003093A1 (fr) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020010223A1 (fr) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
WO2020010107A1 (fr) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
WO2020010200A1 (fr) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
WO2020018459A1 (fr) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Inhibiteurs de capsides pour le traitement du vih |
WO2020028272A1 (fr) | 2018-07-30 | 2020-02-06 | Gilead Sciences, Inc. | Composés anti-vih |
WO2020031112A1 (fr) | 2018-08-09 | 2020-02-13 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020053811A1 (fr) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020058844A1 (fr) | 2018-09-20 | 2020-03-26 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020061163A1 (fr) | 2018-09-19 | 2020-03-26 | Gilead Sciences, Inc. | Inhibiteurs d'intégrase pour la prévention du vih |
WO2020072656A1 (fr) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
US10633375B2 (en) | 2016-08-31 | 2020-04-28 | Jinagsu Hengrui Medicine Co., Ltd | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
WO2020084491A1 (fr) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020084492A1 (fr) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020084480A1 (fr) | 2018-10-25 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020089778A1 (fr) | 2018-10-29 | 2020-05-07 | VIIV Healthcare UK (No.5) Limited | Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
WO2020092621A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués en tant qu'inhibiteurs de hpk1 |
WO2020095177A1 (fr) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020095176A1 (fr) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
WO2020157692A1 (fr) | 2019-02-01 | 2020-08-06 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020176505A1 (fr) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Agonistes de protéine kinase c |
WO2020176510A1 (fr) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Agonistes de protéine kinase c |
WO2020178770A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3'-cycliques et leurs promédicaments |
WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
WO2020197991A1 (fr) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique |
WO2020214647A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un inhibiteur de protéase du vih |
WO2020214652A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un modulateur de récepteur de type toll |
WO2020214716A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Inhibiteurs de la protéase du vih à base de 2-imino-5-oxo-imidazolidine |
WO2020214663A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un modulateur de récepteur de type toll |
WO2020222108A1 (fr) | 2019-04-30 | 2020-11-05 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de réplication du virus de l'immunodéficience humaine |
WO2020236753A1 (fr) | 2019-05-21 | 2020-11-26 | Gilead Sciences, Inc. | Procédés d'identification de patients atteints du vih sensibles à une thérapie avec des anticorps dirigés contre le glycane v3 de la gp120 |
WO2020237025A1 (fr) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
WO2020246910A1 (fr) | 2019-06-03 | 2020-12-10 | Александл Васильевич ИВАЩЕНКО | 9-HYDROXY-1,8-DIOXO-1,3,4, 8-TETRAHYDRO-2Н-PYRIDO[1,2-α] PYRAZINE-7-CARBOXAMIDES ANNELÉS CONSISTANT EN DES INHIBITEURS D'INTÉGRASE DU VIH |
WO2020255038A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyridopyrimidine |
WO2020254985A1 (fr) | 2019-06-19 | 2020-12-24 | VIIV Healthcare UK (No.5) Limited | Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
WO2021011891A1 (fr) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Formulations à action prolongée de ténofovir alafénamide |
WO2021011544A1 (fr) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Vaccins contre le vih et leurs procédés de fabrication et d'utilisation |
WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021064677A1 (fr) | 2019-10-04 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021064571A1 (fr) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021064570A1 (fr) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021070054A1 (fr) | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021108544A1 (fr) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Inhibiteurs de capside pour la prévention du vih |
WO2021130638A1 (fr) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Composés modulant la diacylglycérol kinase |
WO2021173522A1 (fr) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Composés tétracycliques pour le traitement d'une infection par le vih |
WO2021176366A1 (fr) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021176367A1 (fr) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021188959A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation |
WO2021209900A1 (fr) | 2020-04-15 | 2021-10-21 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021236944A1 (fr) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Compositions pharmaceutiques contenant du bictégravir |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021262990A1 (fr) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Inhibiteurs de capside pour le traitement du vih |
WO2022031894A1 (fr) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique |
WO2022072520A1 (fr) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricyclique pontés et leurs utilisations |
WO2022087149A2 (fr) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation |
WO2022103758A1 (fr) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120 |
WO2022159387A1 (fr) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Composés de pyridotriazine substitués et leurs utilisations |
WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
WO2022271650A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
WO2022271684A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
US11548901B2 (en) | 2012-12-21 | 2023-01-10 | Gilead Sciences, Inc. | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections |
WO2023102523A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques pour l'infection par le virus du vih |
WO2023102529A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques pour l'infection par le virus du vih |
WO2023102239A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques contre l'infection par le virus du vih |
WO2023196875A1 (fr) | 2022-04-06 | 2023-10-12 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricycliques pontés et leurs utilisations |
WO2024006982A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih |
WO2024015741A1 (fr) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci |
WO2024044477A1 (fr) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Régime de dosage et de planification pour anticorps largement neutralisants |
WO2024076915A1 (fr) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | Analogues de 4'-thionucléosides et leur utilisation pharmaceutique |
US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
-
2011
- 2011-07-07 CN CN201110190069.1A patent/CN102863512B/zh active Active
-
2012
- 2012-07-06 WO PCT/US2012/045761 patent/WO2013006792A1/fr active Application Filing
Non-Patent Citations (2)
Title |
---|
PORNILLOS ET AL.: "X-ray Structures of the Hexameric Building Block of the HIV Capsid", CELL, vol. 137, 2009, pages 1282 - 1292 * |
SHI ET AL.: "Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization", JOURNAL OF VIROLOGY, vol. 85, January 2011 (2011-01-01), pages 542 - 549 * |
Cited By (209)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034668B2 (en) | 2011-07-06 | 2021-06-15 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US10370358B2 (en) | 2011-07-06 | 2019-08-06 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US11548901B2 (en) | 2012-12-21 | 2023-01-10 | Gilead Sciences, Inc. | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections |
US9012441B2 (en) | 2013-01-09 | 2015-04-21 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2014110297A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Dérivés de (hétéro)arylacétamide servant d'agents antirétroviraux |
WO2014110298A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Hétéroaryles à 5 chaînons et leur utilisation comme agents antiviraux |
WO2014110296A1 (fr) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Composés thérapeutiques pour le traitement d'infections virales |
US9789089B2 (en) | 2013-01-09 | 2017-10-17 | Gilead Sciences, Inc. | Therapeutic compounds |
US9050344B2 (en) | 2013-01-09 | 2015-06-09 | Gilead Sciences, Inc. | Therapeutic compounds |
US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2014134566A2 (fr) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Composés thérapeutiques |
JP2016510038A (ja) * | 2013-03-01 | 2016-04-04 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのアミド化合物 |
EA035127B1 (ru) * | 2013-03-01 | 2020-04-30 | Джилид Сайэнс, Инк. | Терапевтические соединения для лечения инфекции, вызванной вич |
EP3409667A1 (fr) | 2013-03-01 | 2018-12-05 | Gilead Sciences, Inc. | Composés d'amide pour le traitement d'infections à vih |
EP3954679A2 (fr) | 2013-03-01 | 2022-02-16 | Gilead Sciences, Inc. | Composés amides pour le traitement d'infections à vih |
JP2018141018A (ja) * | 2013-03-01 | 2018-09-13 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのアミド化合物 |
US9951043B2 (en) | 2013-03-01 | 2018-04-24 | Gilead Sciences, Inc. | Therapeutic compounds |
EP3954679A3 (fr) * | 2013-03-01 | 2022-04-20 | Gilead Sciences, Inc. | Composés amides pour le traitement d'infections à vih |
WO2014134566A3 (fr) * | 2013-03-01 | 2014-12-24 | Gilead Sciences, Inc. | Composés thérapeutiques |
JP2022009742A (ja) * | 2013-03-01 | 2022-01-14 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのアミド化合物 |
US10456395B2 (en) | 2013-07-12 | 2019-10-29 | Gilead Sciences, Inc. | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections |
US10668064B2 (en) | 2013-07-12 | 2020-06-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US9458159B2 (en) | 2013-07-12 | 2016-10-04 | Gilead Sciences, Inc. | Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections |
US11883397B2 (en) | 2013-07-12 | 2024-01-30 | Gilead Sciences, Inc. | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections |
US9421214B2 (en) | 2013-07-12 | 2016-08-23 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US11213523B2 (en) | 2013-07-12 | 2022-01-04 | Gilead Sciences, Inc. | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections |
EP3252053A1 (fr) | 2013-07-12 | 2017-12-06 | Gilead Sciences, Inc. | Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections par vih |
EP3252058A1 (fr) | 2013-07-12 | 2017-12-06 | Gilead Sciences, Inc. | Composés polycycliques-carbamoylpyridone et leur utilisation pour le traitement des infections par vih |
WO2015006731A1 (fr) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih |
WO2015006733A1 (fr) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
EP3321270A1 (fr) | 2014-06-20 | 2018-05-16 | Gilead Sciences, Inc. | Sodium (2r, 5s, 13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2,5-méthanopyrido [1', 2' : 4.5] pyrazino[2,1-b] oxazepin-8-olate |
EP3564244A1 (fr) | 2014-06-20 | 2019-11-06 | Gilead Sciences, Inc. | Formes cristallines du (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazépine-10-carboxamide |
EP4309736A2 (fr) | 2014-06-20 | 2024-01-24 | Gilead Sciences, Inc. | Formes cristallines de (2r,5s,13a)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13a-octahydro-2,5-méthanopyrido[1',2':4,5!pyrazino[2,1-b [1,3ox-carboxamide-10 |
WO2016036759A1 (fr) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Méthodes de traitement ou de prévention du vih chez des patients au moyen d'une combinaison de ténofovir alafénamide et de dolutégravir |
WO2016106237A1 (fr) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique |
EP3388431A1 (fr) | 2014-12-23 | 2018-10-17 | Gilead Sciences, Inc. | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique |
US11304948B2 (en) | 2014-12-24 | 2022-04-19 | Gilead Sciences, Inc. | Quinazoline compounds |
US9701677B2 (en) | 2014-12-24 | 2017-07-11 | Gilead Sciences, Inc. | Fused pyrimidine compounds |
US10206926B2 (en) | 2014-12-24 | 2019-02-19 | Gilead Sciences, Inc. | Quinazoline compounds |
US9624195B2 (en) | 2014-12-24 | 2017-04-18 | Gilead Sciences, Inc. | Isoquinoline compounds |
US9730936B2 (en) | 2014-12-24 | 2017-08-15 | Gilead Sciences, Inc. | Quinazoline compounds |
US10548898B2 (en) | 2014-12-24 | 2020-02-04 | Gilead Sciences Inc. | Quinazoline compounds |
EP4302830A2 (fr) | 2014-12-24 | 2024-01-10 | Gilead Sciences, Inc. | Derives de quinazoline utilises pour traiter le vih |
EP3521282A1 (fr) | 2014-12-24 | 2019-08-07 | Gilead Sciences, Inc. | Dérivés de quinazoline utilisés pour traiter le vih |
WO2016105534A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Composés isoindoline pour le traitement du vih |
WO2016105564A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Dérivés de quinazoline utilisés pour traiter le vih |
WO2016105532A1 (fr) | 2014-12-24 | 2016-06-30 | Gilead Sciences, Inc. | Composés de pyrimidine fusionnés pour le traitement du vih |
EP3960735A1 (fr) | 2014-12-24 | 2022-03-02 | Gilead Sciences, Inc. | Dérivés de quinazoline utilisés pour traiter le vih |
EP3722297A1 (fr) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Composés modulateurs de récepteurs de type toll |
WO2016141092A1 (fr) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll |
EP3321265A1 (fr) | 2015-03-04 | 2018-05-16 | Gilead Sciences, Inc. | Composés 4,6-diamino-pyrido[3,2-d]pyrimidine et leur utilisation comme modulateurs du récepteurs de type toll |
WO2016161382A1 (fr) | 2015-04-02 | 2016-10-06 | Gilead Sciences, Inc. | Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique |
EP3736274A1 (fr) | 2015-04-02 | 2020-11-11 | Gilead Sciences, Inc. | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique |
WO2017035230A1 (fr) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Modulateurs deutérés du récepteur toll |
WO2017059120A1 (fr) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Composés et combinaisons pour le traitement du vih |
WO2017106346A2 (fr) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Anticorps neutralisants le virus de l'immunodéficience humaine |
EP3992206A1 (fr) | 2015-12-15 | 2022-05-04 | Gilead Sciences, Inc. | Anticorps neutralisateurs humains contre le virus de l'immunodéficience humaine |
EP3597646A1 (fr) | 2016-08-19 | 2020-01-22 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih |
US10654827B2 (en) | 2016-08-19 | 2020-05-19 | Gilead Sciences, Inc. | Therapeutic compounds |
EP4265299A2 (fr) | 2016-08-19 | 2023-10-25 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih |
WO2018035359A1 (fr) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih |
US11993583B2 (en) | 2016-08-19 | 2024-05-28 | Gilead Sciences, Inc. | Therapeutic compounds |
US10071985B2 (en) | 2016-08-19 | 2018-09-11 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2018042332A1 (fr) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons, utilisations et traitements correspondants |
US10633375B2 (en) | 2016-08-31 | 2020-04-28 | Jinagsu Hengrui Medicine Co., Ltd | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
WO2018042331A1 (fr) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons, utilisations et traitements correspondants |
US11084808B2 (en) | 2016-08-31 | 2021-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
WO2018045144A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Composés modulateurs du recepteur de type toll |
WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
WO2018051250A1 (fr) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc |
WO2018064080A1 (fr) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Dérivés d'acide benzothiazol-6-yl-acétique et leur utilisation pour le traitement d'une infection par le vih |
WO2018081292A1 (fr) | 2016-10-27 | 2018-05-03 | Gilead Sciences, Inc. | Formes cristallines de base libre de darunavir, hydrate, solvates et sels de celui-ci |
WO2018127800A1 (fr) | 2017-01-03 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2018127801A1 (fr) | 2017-01-03 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
EP4424374A2 (fr) | 2017-01-31 | 2024-09-04 | Gilead Sciences, Inc. | Formes cristallines de ténofovir alafénamide |
WO2018144390A1 (fr) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Formes cristallines de ténofovir alafénamide |
US10752636B2 (en) | 2017-02-06 | 2020-08-25 | Gilead Sciences, Inc. | HIV inhibitor compounds |
EP3909949A1 (fr) | 2017-02-06 | 2021-11-17 | Gilead Sciences, Inc. | Analogues d'atazanavir (atv) pour le traitement d'infections du vih |
WO2018145021A1 (fr) | 2017-02-06 | 2018-08-09 | Gilead Sciences, Inc. | Analogues d'atazanavir (atv) pour traiter des infections par le vih |
US11078208B1 (en) | 2017-02-06 | 2021-08-03 | Gilead Sciences, Inc. | HIV inhibitor compounds |
US12084455B2 (en) | 2017-02-06 | 2024-09-10 | Gilead Sciences, Inc. | HIV inhibitor compounds |
WO2018203235A1 (fr) | 2017-05-02 | 2018-11-08 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2018237148A1 (fr) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Anticorps multispécifiques ciblant gp120 et cd3 du vih |
WO2019027920A1 (fr) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | Formes cristallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement d'infections virales |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
EP3960740A1 (fr) | 2017-08-01 | 2022-03-02 | Gilead Sciences, Inc. | Formes crystallines de vanillate de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate éthyilique (gs-9131) pour le traitement d'infections virales |
US11266638B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US10849892B2 (en) | 2017-08-17 | 2020-12-01 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US11845739B2 (en) | 2017-08-17 | 2023-12-19 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
EP4382105A2 (fr) | 2017-08-17 | 2024-06-12 | Gilead Sciences, Inc. | Formes de sel de choline d'un inhibiteur de capside de vih |
EP4046994A1 (fr) | 2017-08-17 | 2022-08-24 | Gilead Sciences, Inc. | Formes de sel d'un inhibiteur de capside hiv |
WO2019035904A1 (fr) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc. | Formes solides d'un inhibiteur de capside de vih |
US11267799B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
EP4092020A1 (fr) | 2017-08-17 | 2022-11-23 | Gilead Sciences, Inc. | Formes solides d'un inhibiteur de capside du vih |
WO2019035973A1 (fr) | 2017-08-17 | 2019-02-21 | Gilead Sciences, Inc | Formes de sel choline d'un inhibiteur de la capside du vih |
US11833143B2 (en) | 2017-08-17 | 2023-12-05 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
WO2019040102A1 (fr) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
WO2019057946A1 (fr) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d |
WO2019075291A1 (fr) | 2017-10-13 | 2019-04-18 | Gilead Sciences, Inc. | Dérivés de 1-benzyl-2-imino-4-phényl-5-oxoimidazolidine utilisés en tant qu'inhibiteurs de la protéase du vih |
WO2019084020A1 (fr) | 2017-10-24 | 2019-05-02 | Gilead Sciences, Inc. | Méthodes de traitement de patients co-infectés par un virus et la tuberculose |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11253524B2 (en) | 2018-01-19 | 2022-02-22 | Gilead Sciences, Inc. | Metabolites of bictegravir |
WO2019144015A1 (fr) | 2018-01-19 | 2019-07-25 | Gilead Sciences, Inc. | Métabolites du bictégravir |
US11267801B2 (en) | 2018-02-15 | 2022-03-08 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2019161017A1 (fr) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih |
US11753399B2 (en) | 2018-02-15 | 2023-09-12 | Gilead Sciences, Inc. | Therapeutic compounds |
US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11117886B2 (en) | 2018-02-16 | 2021-09-14 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11760746B2 (en) | 2018-02-16 | 2023-09-19 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
WO2019193543A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3'-cycliques |
US11149052B2 (en) | 2018-04-06 | 2021-10-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides |
US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
WO2019193533A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 2'2'-cycliques |
WO2019193542A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 2'3'-cycliques |
WO2019198024A1 (fr) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
WO2019244066A2 (fr) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020003093A1 (fr) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020010107A1 (fr) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
EP4257600A2 (fr) | 2018-07-03 | 2023-10-11 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020010223A1 (fr) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
US11098027B2 (en) | 2018-07-06 | 2021-08-24 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020010200A1 (fr) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
US11944611B2 (en) | 2018-07-16 | 2024-04-02 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2020018459A1 (fr) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Inhibiteurs de capsides pour le traitement du vih |
WO2020028272A1 (fr) | 2018-07-30 | 2020-02-06 | Gilead Sciences, Inc. | Composés anti-vih |
US11052087B2 (en) | 2018-07-30 | 2021-07-06 | Gilead Sciences, Inc. | Anti-HIV compounds |
WO2020031112A1 (fr) | 2018-08-09 | 2020-02-13 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020053811A1 (fr) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020061163A1 (fr) | 2018-09-19 | 2020-03-26 | Gilead Sciences, Inc. | Inhibiteurs d'intégrase pour la prévention du vih |
WO2020058844A1 (fr) | 2018-09-20 | 2020-03-26 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020072656A1 (fr) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
WO2020084491A1 (fr) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020084492A1 (fr) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020084480A1 (fr) | 2018-10-25 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020089778A1 (fr) | 2018-10-29 | 2020-05-07 | VIIV Healthcare UK (No.5) Limited | Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020092621A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués en tant qu'inhibiteurs de hpk1 |
WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
EP4371987A1 (fr) | 2018-10-31 | 2024-05-22 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1 |
WO2020095176A1 (fr) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020095177A1 (fr) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020157692A1 (fr) | 2019-02-01 | 2020-08-06 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020176505A1 (fr) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Agonistes de protéine kinase c |
WO2020176510A1 (fr) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Agonistes de protéine kinase c |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
WO2020178770A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3'-cycliques et leurs promédicaments |
WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
CN109824756A (zh) * | 2019-03-19 | 2019-05-31 | 山东大学 | 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用 |
CN109824756B (zh) * | 2019-03-19 | 2022-03-22 | 山东大学 | 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用 |
WO2020197991A1 (fr) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique |
EP4122537A1 (fr) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Composés tricycliques pontés de carbamoylpyridone et leur utilisation pharmaceutique |
WO2020214716A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Inhibiteurs de la protéase du vih à base de 2-imino-5-oxo-imidazolidine |
WO2020214663A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un modulateur de récepteur de type toll |
WO2020214652A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un modulateur de récepteur de type toll |
WO2020214647A1 (fr) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Formes solides d'un inhibiteur de protéase du vih |
WO2020222108A1 (fr) | 2019-04-30 | 2020-11-05 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de réplication du virus de l'immunodéficience humaine |
WO2020236753A1 (fr) | 2019-05-21 | 2020-11-26 | Gilead Sciences, Inc. | Procédés d'identification de patients atteints du vih sensibles à une thérapie avec des anticorps dirigés contre le glycane v3 de la gp120 |
WO2020237025A1 (fr) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
WO2020246910A1 (fr) | 2019-06-03 | 2020-12-10 | Александл Васильевич ИВАЩЕНКО | 9-HYDROXY-1,8-DIOXO-1,3,4, 8-TETRAHYDRO-2Н-PYRIDO[1,2-α] PYRAZINE-7-CARBOXAMIDES ANNELÉS CONSISTANT EN DES INHIBITEURS D'INTÉGRASE DU VIH |
WO2020255038A1 (fr) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyridopyrimidine |
WO2020254985A1 (fr) | 2019-06-19 | 2020-12-24 | VIIV Healthcare UK (No.5) Limited | Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
WO2021011544A1 (fr) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Vaccins contre le vih et leurs procédés de fabrication et d'utilisation |
WO2021011891A1 (fr) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Formulations à action prolongée de ténofovir alafénamide |
WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
WO2021064571A1 (fr) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021064570A1 (fr) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021064677A1 (fr) | 2019-10-04 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021070054A1 (fr) | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021108544A1 (fr) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Inhibiteurs de capside pour la prévention du vih |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
WO2021130638A1 (fr) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Composés modulant la diacylglycérol kinase |
WO2021173522A1 (fr) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Composés tétracycliques pour le traitement d'une infection par le vih |
WO2021176367A1 (fr) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021176366A1 (fr) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021188959A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation |
WO2021209900A1 (fr) | 2020-04-15 | 2021-10-21 | VIIV Healthcare UK (No.5) Limited | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
WO2021236944A1 (fr) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Compositions pharmaceutiques contenant du bictégravir |
US12077537B2 (en) | 2020-06-25 | 2024-09-03 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2021262990A1 (fr) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Inhibiteurs de capside pour le traitement du vih |
WO2022031894A1 (fr) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique |
WO2022072520A1 (fr) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricyclique pontés et leurs utilisations |
WO2022087149A2 (fr) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation |
WO2022103758A1 (fr) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120 |
EP4321217A2 (fr) | 2021-01-19 | 2024-02-14 | Gilead Sciences, Inc. | Composés de pyridotriazine substitués et leurs utilisations |
WO2022159387A1 (fr) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Composés de pyridotriazine substitués et leurs utilisations |
WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
WO2022271684A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
WO2022271650A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
WO2023102523A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques pour l'infection par le virus du vih |
WO2023102529A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques pour l'infection par le virus du vih |
WO2023102239A1 (fr) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Composés thérapeutiques contre l'infection par le virus du vih |
EP4310087A1 (fr) | 2022-04-06 | 2024-01-24 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricycliques pontés et leurs utilisations |
WO2023196875A1 (fr) | 2022-04-06 | 2023-10-12 | Gilead Sciences, Inc. | Composés de carbamoylpyridone tricycliques pontés et leurs utilisations |
WO2024006982A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih |
WO2024015741A1 (fr) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci |
WO2024044477A1 (fr) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Régime de dosage et de planification pour anticorps largement neutralisants |
WO2024076915A1 (fr) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | Analogues de 4'-thionucléosides et leur utilisation pharmaceutique |
Also Published As
Publication number | Publication date |
---|---|
CN102863512A (zh) | 2013-01-09 |
CN102863512B (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013006792A1 (fr) | Composés antiviraux | |
WO2012065062A1 (fr) | Nouveaux composés antiviraux | |
EP3268003B1 (fr) | Thénopyrazines inhibitrices de l'activité de l'irak4 | |
AU2015342887B2 (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders | |
CA3079617A1 (fr) | Antagonistes du recepteur muscarinique de l'acetylcholine m4 | |
US20020016309A1 (en) | Imidazopyridine and imidazopyrimidine antiviral agents | |
CA3074459A1 (fr) | Inhibiteurs d'egfr et/ou de her2 et procedes d'utilisation | |
EP3268006A1 (fr) | Inhibiteurs de pyrrolotriazine de l'activité d'irak4 | |
RU2601742C2 (ru) | Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций | |
CA2585373A1 (fr) | Pyrazoles a substitution 5-carboxyamide et [1,2,4]triazoles utilises en tant qu'agents antiviraux | |
WO2012021796A2 (fr) | Nouveaux dérivés de cyclosporine destinés à la prévention ou au traitement d'une infection virale | |
WO2017192841A1 (fr) | Méthodes de traitement et polythérapies faisant appel à des composés hétérobicycliques activateurs de gcase et autres composés apparentés | |
AU2001272906A1 (en) | Imidazopyridine and imidazopyrimidine antiviral agents | |
US10246414B2 (en) | Allosteric modulators of CB1 cannabinoid receptors | |
CA3081324A1 (fr) | Antagonistes du recepteur muscarinique m4 a l'acetylcholine | |
AU2015336035A1 (en) | Ethyl n-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | |
CA3083061A1 (fr) | Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de l'histone desacetylase 6 | |
AU2024202195A1 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
AU2021261002A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
ES2820585T3 (es) | Composiciones y métodos anti-HCMV | |
CA2946062C (fr) | Composes pour traiter des infections virales | |
EP4313313A1 (fr) | Composés hétérocycliques aryles comme bloqueurs des canaux potassiques shaker kv1.3 | |
ZA200210104B (en) | Imidazopyridine and imidazopyrimidine antiviral agents. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12808071 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12808071 Country of ref document: EP Kind code of ref document: A1 |